24 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
included $13.4 million of non-cash stock-based compensation expense. The decrease was primarily driven by the wind down of clinical studies involving VIR
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
with BARDA supporting the wind down of the Company’s Phase 2 PENINSULA trial in the third quarter of 2023.
Cost of Revenue: Cost of revenue
8-K
fj1xvoej
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
S-3ASR
9xsd6vkft2wjko30yr
10 Nov 20
Automatic shelf registration
5:13pm
DRS
EX-10.56
6y0h b0okexipyif
23 Jun 20
Draft registration statement
12:00am
DRS
EX-10.58
2wo25qz
23 Jun 20
Draft registration statement
12:00am
DRS
EX-10.54
2ll68b
23 Jun 20
Draft registration statement
12:00am
S-1
EX-10.16
y2byd9 17tbw23ebg
3 Sep 19
IPO registration
4:40pm